Eli Chapman, PhD
Cancer Biology Program
-
Associate Professor, Pharmacology & Toxicology
Biography
I completed by BS in chemistry at UC, Berkeley; my MA at Columbia University in Organic Chemistry; and my PhD at The Scripps Research Institute in Organic Chemistry. I was an HHMI and NRSA postdoc at Yale School of Medicine in the Department of Genetics. I joined the University of Arizona in 2012.
Cancer Focus
I work on drug discovery and development. My primary interests are cellular quality control and protection mechanisms including molecular chaperones and NRF2.
Selected Publications
M. Dodson, de la Vega, M. Rojo, Cholanians, A. B., Schmidlin, C. J., Chapman, E., and Zhang, D. D., “Modulating NRF2 in Disease: Timing Is Everything.”, Annu Rev Pharmacol Toxicol, vol. 59, pp. 555-575, 2019. PMID: 30256716
M. Dodson, Liu, P., Jiang, T., Ambrose, A. J., Luo, G., de la Vega, M. Rojo, Cholanians, A. B., Wong, P. Kin, Chapman, E., and Zhang, D. D., “Increased O-GlcNAcylation of SNAP29 drives arsenic-induced autophagic dysfunction.”, Mol Cell Biol, 2018. PMCID: PMC5954189 PMID: 29507186
T. L. Peters, Tillotson, J., Yeomans, A. M., Wilmore, S., Lemm, E., Jiménez-Romero, C., Amador, L. A., Li, L., Amin, A. D., Pongtornpipat, P., Zerio, C. J., Ambrose, A. J., Paine-Murrieta, G., Greninger, P., Vega, F., Benes, C. H., Packham, G., Rodríguez, A. D., Chapman, E., and Schatz, J. H., “Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with Antitumor Activity.”, Clin Cancer Res, vol. 24, no. 17, pp. 4256-4270, 2018. PMID: 29844128
M. Rojo de la Vega, Chapman, E., and Zhang, D. D., “NRF2 and the Hallmarks of Cancer.”, Cancer Cell, vol. 34, no. 1, pp. 21-43, 2018. PMCID: PMC6039250 PMID: 29731393
J. Tillotson, Kedzior, M., Guimarães, L., Ross, A. B., Peters, T. L., Ambrose, A. J., Schmidlin, C. J., Zhang, D. D., Costa-Lotufo, L. V., Rodríguez, A. D., Schatz, J. H., and Chapman, E., “ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.”, Bioorg Med Chem Lett, vol. 27, no. 17, pp. 4082-4085, 2017. PMCID: PMC5593424 PMID: 28757063
A. J. Ambrose, Santos, E. A., Jimenez, P. C., Rocha, D. D., Wilke, D. V., Beuzer, P., Axelrod, J., Kanduluru, A. Kumar, Fuchs, P. L., Cang, H., Costa-Lotufo, L. V., Chapman, E., and La Clair, J. J., “Ritterostatin G 1 , a Cephalostatin-Ritterazine Bis-steroidal Pyrazine Hybrid, Selectively Targets GRP78.”, Chembiochem, vol. 18, no. 6, pp. 506-510, 2017. PMCID: PMC5562448 PMID: 28074539
J. Tillotson, Bashyal, B. P., Kang, M. J., Shi, T., De La Cruz, F., Gunatilaka, A. A. Leslie, and Chapman, E., “Selective inhibition of p97 by chlorinated analogues of dehydrocurvularin.”, Org Biomol Chem, vol. 14, no. 25, pp. 5918-21, 2016. PMCID: PMC5466822 PMID: 27223265
S. Tao, Wang, S., Moghaddam, S. Javad, Ooi, A., Chapman, E., Wong, P. K., and Zhang, D. D., “Oncogenic KRAS confers chemoresistance by upregulating NRF2.”, Cancer Res, vol. 74, no. 24, pp. 7430-41, 2014. PMCID: PMC4268230 PMID: 25339352